References
- DelaugerreCPeytavinGDominguezSVirological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097)J Med Virol200577334535016173015
- DuvalXPeytavinGAlbertIDetermination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patientsHIV Med20045430731315236622
- HawkinsTAppearance-related side effects of HIV-1 treatmentAIDS Patient Care STDS200620161816426151
- NowacekAGendelmanHENanoART, neuroAIDS and CNS drug deliveryNanomed200945557574
- Shehu-XhilagaMTachedjianGCroweSMKedzierskaKAntiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV–1Curr Med Chem200512151705171916029143
- AlosLNavarretePMorenteVImmunoarchitecture of lymphoid tissue in HIV-infection during antiretroviral therapy correlates with viral persistenceMod Pathol200518112713615389256
- BestBMLetendreSLBrigidELow atazanavir concentrations in cerebrospinal fluidAids2009231838719050389
- MurriRLepriACCicconiPIs moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian cohort of antiretroviral-naive patients studyJ Acquir Immune Defic Syndr2006411233016340469
- PathanSAIqbalZZaidiSMCNS drug delivery systems: novel approachesRecent Pat Drug Deliv Formul200931718919149731
- VaratharajanLThomasSAThe transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further researchAntiviral Res2009822A9910919176219
- NowacekASBalkundiSMcMillanJAnalyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophagesJ Control Release2011150220421121108978
- NowacekASMcMillanJMillerRAndersonARabinowBGendelmanHENanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeuticsJ Neuroimmune Pharmacol20105459260120237859
- DouHDestacheCJMoreheadJRDevelopment of a macrophage- based nanoparticle platform for antiretroviral drug deliveryBlood200610882827283516809617
- DouHGrotepasCBMcMillanJMMacrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDSJ Immunol2009183166166919535632
- NowacekASMillerRLMcMillanJNanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug deliveryNanomedicine (Lond)20094890391719958227
- BalkundiSNowacekASRoyUMartinez-SkinnerAMcMillanJGendelmanHEMethods development for blood borne macrophage carriage of nanoformulated antiretroviral drugsJ Vis Exp201046 pii: 246010.3791/2460
- BressaniRFNowacekASSinghSPharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriageNanotoxicology2010559260521175298
- CorriasFLaiFNew methods for lipid nanoparticles preparationRecent Pat Drug Deliv Formul20115320121321834772
- DestacheCJBelgumTGoedeMShibataABelshanMAAntiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in miceJ Antimicrob Chemother201065102183218720729545
- DouHMoreheadJDestacheCJLaboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophagesVirology2007358114815816997345
- MainardesRMEvangelistaRCPLGA nanoparticles containing praziquantel: effect of formulation variables on size distributionInt J Pharm20052901–213714415664139
- RabinowBENanosuspensions in drug deliveryNat Rev Drug Discov20043978579615340388
- ShegokarRJanschMSinghKKMullerRHIn vitro protein adsorption studies on nevirapine nanosuspensions for HIV/AIDS chemotherapyNanomedicine20117333334021094278
- TakatsukaTEndoTJianguoYYuminokiKHashimotoNNanosizing of poorly water soluble compounds using rotation/revolution mixerChem Pharm Bull (Tokyo)200957101061106719801859
- NakaraniMPatelPPatelJMurthyRSVaghaniSSCyclosporine a-nanosuspension: formulation, characterization and in vivo comparison with a marketed formulationSci Pharm201078234536121179351
- NiwaTMiuraSDanjoKUniversal wet-milling technique to prepare oral nanosuspension focused on discovery and preclinical animal studies – Development of particle design methodInt J Pharm20114051–221822721167922
- DestacheCJBelgumTChristensenKCombination antiretroviral drugs in PLGA nanoparticle for HIV-1BMC Infect Dis2009919820003214
- ReddyMKWuLKouWGhorpadeALabhasetwarVSuperoxide dismutase-loaded PLGA nanoparticles protect cultured human neurons under oxidative stressAppl Biochem Biotechnol20081512–356557718509606
- GendelmanHEOrensteinJMMartinMAEfficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytesJ Exp Med19881674142814413258626
- KalterDCNakamuraMTurpinJAEnhanced HIV replication in macrophage colony-stimulating factor-treated monocytesJ Immunol199114612983061701795
- SwindellsSDiRienzoAGWilkinTRegimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppressionJAMA2006296780681416905786
- SwindellsSFlexnerCFletcherCVJacobsonJMThe critical need for alternative antiretroviral formulations, and obstacles to their developmentJ Infect Dis2011204566967421788451
- DeeksEDPerryCMEfavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla(R)): a review of its use in the management of HIV infectionDrugs201070172315233821080746
- KadiuINowacekAcMillanJGendelmanHEMacrophage endocytic trafficking of antiretroviral nanoparticlesNanomedicine201161254221182416
- JohnsonMGrinsztejnBRodriguezCAtazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failuresAids200519768569415821394
- MartinsSRamosMJFernandesPAThe current status of the NNRTI family of antiretrovirals used in the HAART regime against HIV infectionCurr Med Chem200815111083109518473804
- HaasDWRibaudoHJKimRBPharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group studyAids200418182391240015622315
- MurrayJLMavrakisMMcDonaldNJRab9 GTPase is required for replication of human immunodeficiency virus type 1, filoviruses, and measles virusJ Virol20057918117421175116140752
- VarthakaviVSmithRMMartinKLThe pericentriolar recycling endosome plays a key role in Vpu-mediated enhancement of HIV-1 particle releaseTraffic20067329830716497224